SEC Tracker
Get the app

BioMarin Pharmaceutical BMRN

BioMarin announces Alesta acquisition charges

Form
8-K
Filed
Importance
Routine
  1. Acquired IPR&D charge of $283M for Q3 2026
  2. Estimated EPS impact of $1.50 for Q3 2026
  3. Full-year 2026 charges expected at $320M
  4. No updated full-year guidance yet

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when BioMarin Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Repligen RGEN public float $6.0B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025